- $1.77bn
- $1.24bn
- $68.56m
Brief: Vir Biotechnology Inc's Executive Vice President And Chief Operating Officer, Johanna Friedl-Naderer, Will Be Leaving Co On Sept 29
U.S. STOCKS ON THE MOVE-Asbury, natgas firms, energy firms
Vir hits record low as BofA downgrades to 'neutral'
Vir Biotechnology Inc reports results for the quarter ended in June - Earnings Summary
Brief: Vir Biotechnology Q2 EPS USD -1.45
Vir Biotechnology Inc expected to post a loss of $1.20 a share - Earnings Preview
Brief: Vir Biotechnology To Provide Business Update And Report Q2 2023 Financial Results On August 3, 2023
Vir Biotech slumps to over 3-year low as flu prevention therapy fails trial
Vir Biotech slumps as flu therapy fails in mid-stage study
Brief: Vir Biotechnology Announces Topline Data From Phase 2 Peninsula Trial Evaluating Vir-2482 For Prevention Of Seasonal Influenza A Illness
Ultragenyx appoints new CFO, shares fall
Brief: Vir Biotechnology Presents New Data Evaluating The Potential For Vir-2218 And Vir-3434 As Therapies For Chronic Hepatitis B And Hepatitis D
Vir Biotechnology Inc reports results for the quarter ended in March - Earnings Summary
Brief: Vir Biotechnology Receives Expanded Support To Develop Its Novel T Cell Vaccine Platform With New $10 Million Grant For HIV Prevention
Vir Biotechnology Inc expected to post a loss of 87 cents a share - Earnings Preview
SVB fall casts shadow on early-stage U.S. biotech
Brief: Vir Biotechnology Maintains Operating Accounts At SVB With About $220 Mln As Of March 10
U.S. STOCKS ON THE MOVE-CrowdStrike, Dentsply Sirona, Qualtrics
Vir Biotech gains as JP Morgan raises to 'overweight'